Holman, Rury R.

Insulin deficiency and insulin resistance interaction in diabetes: Estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations

Turner, R. C., Holman, R. R., Matthews, D., Hockaday, T. D. R., & Peto, J. (1979) · Metabolism

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 388

United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy

Wright, A., Cull, C., Holman, R. R., Turner, R., Murchison, L., WRIGHT, A., Oakley, N., Kohner, E., Hayes, R., Scarpello, J., et al. (1998) · Annals of Internal Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 385

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Holman, R. R., Coleman, R. L., Chan, J. C. N., Chiasson, J.-L., Feng, H., Ge, J., Gerstein, H. C., Gray, R., Huo, Y., Lang, Z., et al. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 323

Empagliflozin in acute myocardial infarction: the EMMY trial

von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., et al. (2022) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 303

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis

Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet

Health Systems, Economic Evaluations, Quality of LifeHealth Promotion and Cardiovascular Prevention

Cited by 287

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT

Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 249

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis

Yates, T., Haffner, S. M., Schulte, P. J., Thomas, L., Huffman, K. M., Bales, C. W., Califf, R. M., Holman, R. R., McMurray, J. J. V., Bethel, M. A., et al. (2014) · The Lancet

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 238

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 227

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 217

Assessing the potential for α-glucosidase inhibitors in prediabetic states

Holman, R. R. (1998) · Diabetes Research and Clinical Practice

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 197

Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated With Improved Outcomes?

Colagiuri, S., Cull, C. A., Holman, R. R., & For the UKPDS Group (2002) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 183

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).

Adler, A. I., Coleman, R. L., Leal, J., Whiteley, W. N., Clarke, P., & Holman, R. R. (2024) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 166

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)

Clarke, P. M., Gray, A. M., Briggs, A., Stevens, R. J., Matthews, D. R., Holman, R. R., & (UKPDS), O. B. O. T. U. P. D. S. (2005) · Diabetologia

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 155

Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.

Wright, A. D., Cull, C. A., Macleod, K. M., & Holman, R. R. (2006) · Journal of Diabetes and its Complications

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 153

Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88

Lind, M., Imberg, H., Coleman, R. L., Nerman, O., & Holman, R. R. (2021) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 128

Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial

Bethel, M. A., Mentz, R. J., Merrill, P., Buse, J. B., Chan, J. C., Goodman, S. G., Iqbal, N., Jakuboniene, N., Katona, B., Lokhnygina, Y., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 112

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes: Insights From the EXSCEL Trial

Fudim, M., White, J., Pagidipati, N. J., Lokhnygina, Y., Wainstein, J., Murin, J., Iqbal, N., Öhman, P., Lopes, R. D., Reicher, B., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 99

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51)

Clarke, P., Gray, A., Adler, A., Stevens, R., Raikou, M., Cull, C., Stratton, I., & Holman, R. (2001) · Diabetologia

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 99

Real-world studies no substitute for RCTs in establishing efficacy

Gerstein, H. C., McMurray, J., & Holman, R. R. (2019) · The Lancet

Advanced Causal Inference TechniquesStatistical Methods in Clinical Trials

Cited by 97

A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk

Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine

Lipoproteins and Cardiovascular HealthCardiovascular Health and Risk Factors

Cited by 97

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 94

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial

Holman, R. R., Paul, S., Farmer, A., Tucker, L., Stratton, I. M., Neil, H. A. W., & on behalf of the AFORRD study group (2009) · Diabetologia

Lipoproteins and Cardiovascular HealthFatty Acid Research and Health

Cited by 81

Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the tecos trial

Sharma, A., Green, J. B., Dunning, A., Lokhnygina, Y., Al-Khatib, S. M., Lopes, R. D., Buse, J. B., Lachin, J. M., Van de Werf, F., Armstrong, P. W., et al. (2017) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 80

Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype

Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 76